EAST RUTHERFORD, N.J., March 22 /PRNewswire-FirstCall/ -- Cambrex Corporation announced it has acquired IEP GmbH ("IEP"), a privately held company that is a leader in the field of industrial biocatalysis. IEP is located in Wiesbaden, Germany and offers cost effective customized biocatalytic process development and sales of enzymes to the pharmaceutical industry, with the ability to utilize its tool box of over 100 proprietary biocatalytic enzymes. IEP "bioreduction" technologies have been successfully used in numerous commercialized processes.
The business will be renamed Cambrex IEP and will remain in Wiesbaden, Germany. For more information on IEP, please visit www.biocatalysis.com.
Cambrex provides products and services to accelerate the development and commercialization of small molecule active pharmaceutical ingredients ("APIs"), advanced intermediates and other products for branded and generic pharmaceuticals. The Company currently employs approximately 850 people worldwide. For more information, please visit www.cambrex.com.
Cambrex Corporation
